VEXAS Syndrome Clinical Trials

13 clinical trials for VEXAS Syndrome across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome — RECRUITING · PHASE1
• Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection — RECRUITING
• A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) — RECRUITING · PHASE2
• Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study — RECRUITING
• AutoInflammatory Disease Alliance Registry (AIDA) — RECRUITING
• PAXIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-FINDING PHASE 2 STUDY (PART 1) FOLLOWED BY AN OPEN-LABEL PERIOD (PART 2) TO ASSESS THE EFFICACY AND SAFETY OF PACRITINIB IN PATIENTS WITH VEXAS SYNDROME — RECRUITING · PHASE2
• A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period — NOT_YET_RECRUITING · PHASE2
• A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX) — NOT_YET_RECRUITING · PHASE2
• Clinical Phenotype and Prevalence of VEXAS Syndrome in Internal Medicine — NOT_YET_RECRUITING
• PAXIS: A randomized, double-blind, placebo-controlled dose-finding phase 2 study (Part 1) followed by an open-label period (Part 2) to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome — TERMINATED · PHASE2
• A RANDOMIZED PHASE 2/3, DOUBLE-BLIND, PLACEBO-CONTROLLED ADAPTIVE STUDY EVALUATING THE EFFICACY AND SAFETY OF MOMELOTINIB IN PARTICIPANTS WITH VEXAS SYNDROME — NOT_YET_RECRUITING · PHASE2
• A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome — NOT_YET_RECRUITING · PHASE2
• Clonal Hematopoiesis of Immunological Significance — NOT_YET_RECRUITING

Refine this search